We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Checkpoint Therapeutics Inc | NASDAQ:CKPT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.15 | 10.14% | 1.63 | 1.58 | 1.67 | 1.6969 | 1.47 | 1.48 | 619,360 | 00:56:35 |
| | |
Per share
|
| |
Total
|
| ||||||
Public offering price
|
| | | $ | | | | | $ | | | ||
Underwriting discount and commissions
(1)
|
| | | $ | | | | | | $ | | | |
Proceeds to Checkpoint, before expenses
|
| | | $ | | | | | | $ | | | |
| | |
Page
|
| |||
About this prospectus supplement | | | | | S-ii | | |
| | | | S-iii | | | |
| | | | S-5 | | | |
| | | | S-11 | | | |
| | | | S-14 | | | |
| | | | S-15 | | | |
| | | | S-16 | | | |
| | | | S-17 | | | |
| | | | S-20 | | | |
| | | | S-23 | | | |
| | | | S-23 | | | |
| | | | S-23 | | | |
| | | | S-23 | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 12 | | | |
| | | | 13 | | | |
| | | | 14 | | | |
| | | | 14 | | |
September 30, 2017 (unaudited)
|
| |
Actual
|
| |
As Adjusted
|
| ||||||
| | |
(in thousands, except share data)
|
| |||||||||
Cash and cash equivalents
|
| | | | 23,418 | | | | | | | | |
Stockholders’ equity: | | | | ||||||||||
Class A Common Stock, $0.0001 par value per share, 15,000,000 shares authorized; 7,000,000 issued and outstanding, actual and as adjusted
|
| | | | 1 | | | | | | | | |
Common stock, $0.0001 par value per share, 35,000,000 shares authorized; 18,368,575 shares actual and shares as adjusted, issued and outstanding
|
| | | | 2 | | | | | | | | |
Additional paid-in capital
|
| | | | 72,926 | | | | | | | | |
Common Stock Issuable, 0 shares actual and as adjusted
|
| | | | — | | | | | | — | | |
Accumulated deficit
|
| | | | (53,112 ) | | | | | | | | |
Total stockholders’ equity
|
| | | | 19,817 | | | | | | | | |
Total capitalization
|
| | | | 19,817 | | | | | | | | |
|
|
Public offering price per share
|
| | | $ | | | |
|
Net tangible book value per share as of September 30, 2017
|
| | | $ | 0.78 | | |
|
Increase per share attributable to this offering
|
| | | $ | | | |
|
As adjusted net tangible book value per share as of September 30, 2016 after this offering
|
| | | $ | | | |
|
Dilution per share to new investors participating in this offering
|
| | | $ | | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 8 | | | |
| | | | 9 | | | |
| | | | 12 | | | |
| | | | 13 | | | |
| | | | 14 | | | |
Experts | | | | | 14 | | |
1 Year Checkpoint Therapeutics Chart |
1 Month Checkpoint Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions